Synthesis and anti-HIV activity of [d4U]-[trovirdine analogue] and [d4T]-[trovirdine analogue] heterodimers as inhibitors of HIV-1 reverse transcriptase

Nucleosides, Nucleotides and Nucleic Acids

Volumn 21, Issue 8-9, 2002, Pages 505-533

  Gavriliu, D ^a   Fossey, C ^a   Ciurea, A ^a   Delbederi, Z ^a   Sugeac, E ^a   Laduree D ^a   Schmidt, S ^b   Laumond, G ^b   Aubertin, A M ^b  

^a UNIVERSITÉ DE CAEN   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; TROVIRDINE; 2',3' DIDEHYDRO 2',3' DIDEOXYURIDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 2',3'-DIDEHYDRO-2',3'-DIDEOXYURIDINE; PYRIDINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; EVALUATION; REACTION ANALYSIS; STRUCTURE ANALYSIS; VIRUS REPLICATION; CELL CULTURE; CHEMISTRY; COMPARATIVE STUDY; DIMERIZATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LYMPHOCYTE; SYNTHESIS; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DIMERIZATION; DRUG EVALUATION, PRECLINICAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LYMPHOCYTES; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TUMOR CELLS, CULTURED; ZIDOVUDINE;

EID: 0036445890     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-120015066     Document Type: Article

References (43)

1. De Clercq, E. Toward improved anti-HIC chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
2. Balzarini, J. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm. World Sci. 1994, 16, 113-126.
3. Herdewijn, P.; Balzarini, J.; De Clercq, E. In Advances in Antiviral Drug Design; De Clercq, E., Ed.; JAI Press Inc.: Greenwich, London, 1993; Vol. 1, 233-318.
4. Young, S.D. Perspect. Drug Discovery Des. 1993, 1, 181-192.
5. De Clercq, E. HIV-1-specific RT inhibitors: Highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase. Med. Res. Rev. 1993, 13, 229-258.
6. De Clercq, E. Non-nucleoside reverse transcriptase inhibitors (NNRTIS) for the treatment of human immunodeficiency virus type 1 9HIV-1) infections: Strategies to overcome drug resistance development. Med. Res. Rev. 1996, 16, 125-157.
7. De Clercq, E. The Role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in a the therapy of HIV-1 infection. Antiviral Res. 1998, 38, 153-179.
8. Pedersen, E.B. Non-nucleoside reverse transcriptase inhibitors: The NNRTI boom. Antiviral Chem. Chemother. 1999, 10 (6), 285-314.
9. De Clercq, E. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 1994, 47, 155-169.
10. Mellors, J.W.; Bazmi, H.Z.; Schinazi, R.F.; Roy, B.M.; Hsiou, Y.; Arnold, E.; Weir, J.; Mayers, D.L. Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrobial agents and chemotherapy 1995, 39 (5), 1087-92.
11. Schmit, J.C.; Cogniaux, J.; Hermans, P.; Van Vaeck, C.; Sprecher, S.; Van Memoortel, B.; Witvrouw, M.; Balzarini, J.; Desmyter, J.; De Clercq, E.; Vandamme, A.M. Related articles, nucleotide, protein. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 1996, 174, 962-968.
12. Vandamme, A.M.; Van Vaerenbergh, K.; De Clercq, E. Anti-human immunodeficiency virus drug combination strategies. Antiviral Chem. Chemother. 1998, 9, 187-203.
13. D'Aquila, R.T.; Hughes, M.D.; Johnson, V.A.; Fischl, M.A.; Sommadossi, J.-P.; Liou, S.-H.; Timpone, J.; Myers, M.; Basgoz, N.; Niu, M.; Hirsch, M.S. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, doubleblind, placebo-controlled trial. National Institute of Allergy and Infections Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann. Int. Med. 1996, 124, 1019-1030.
14. Goldman, M.E.; Nunberg, J.H.; O'Brien, J.A.; Quintero, J.C.; Schleif, W.A.; Freund, K.F.; Gaul, S.L.; Saari, W.S.; Wai, J.S.; Hoffman, J.M.; Anderson, P.S.; Hupe, D.J.; Emini, E.A.; Stern, A.M. Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6863-6867.
15. Schooley, R.T.; Campbell, T.B.; Kuritzkes, D.R.; Blaschke, T.; Stein, D.S.; Rosandlich, M.E.; Phair, J.; Pottage, J.C.; Messari, F.; Collier, A.; Kahn, J.; Ray, G.; Curtis, S.; Bakhtiari, M.; Kessler, H.; Coombs, R.; Corey, L.; Volberding, P.; Calandra, G.; Massari, F.J. Phase 1 study of combination therapy with L-697,661 and zidovudine. The ACTG 184 protocol team. Acquired Immune Defic. Syndr. Hum. Retrovirol. 1996, 12, 363-370.
16. Chong, K.-T.; Pagano, P.J. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine. Antiviral Res. 1997, 34, 51-63.
17. Davey, R.T. Jr.; Chaitt, D.G.; Reed, G.F.; Freimuth, W.W.; Herpin, B.R.; Metcalf, J.A.; Eastman, P.S.; Falloon, J.; Kovacs, J.A.; Polis, M.A.; Walker, R.E.; Masur, H.; Boyle, J.; Coleman, S.; Cox, S.R.; Wathen, L.; Daenzer, C.L.; Lane, H.C. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 1996, 40, 1657-1664.
18. Piras, G.; Nakade, K.; Yuasa, S.; Baba, M. Three-drug combination of MKC-442, lamivudine and zidovudine in vitro: Potential approach towards effective chemotherapy against HIV-1. AIDS 1997, 11, 469-475.
19. Brennan, T.M.; Taylor, D.L.; Bridges, C.G.; Leyda, J.P.; Tyms, A.S. The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase. Antiviral Res. 1995, 26, 173-187.
20. Spence, R.A.; Kati, W.M.; Anderson, K.S.; Johnson, K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267, 988-993.
21. Rittinger, K.; Divita, G.; Goody, R.S. Human Immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 8046-8049.
22. Nanni, R.G.; Ding, J.; Jacobo-Molina, A.; Hughes, S.H.; Arnold, E. Perspect. Drug Discover 1993, 1, 129-150.
23. Smerdon, S.J.; Jäger, J.; Wang, J.; Kohlstaedt, L.A.; Chirino, A.J.; Friedman, J.M.; Rice, P.A.; Steitz, T.A. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 3911-3915.
24. Velázquez, S.; Alvarez, R.; San-Félix, A.; Jimeno, M.L.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Synthesis and Anti-HIV activity of [AZT]-[TSAO-T] and [AZT]-[HEPT] dimers as potential multifunctional inhibitors of HIV-1 reverse transcriptase. J. Med. Chem. 1995, 38, 1641-1649.
25. Renoud-Grappin, M.; Fosssey, C.; Fontaine, G.; Ladurée, D.; Aubertin, A.M.; Kirn, A. Imidazo[1,5-b]pyridazine-d4T conjugates: Synthesis and anti-human immunodeficiency virus evaluation. Antiviral Chem. Chemother. 1998, 9, 205-223.
26. Velázquez, S.; Tuñón, V.; Jimeno, M.L.; Chamorro, C.; De Clercq, E.; Balzarini, J.; Camarasa, M.J. Potential multifunctional inhibitors of HIV-1 reverse transcriptase, novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region. J. Med. Chem. 1999, 42, 5188-5196.
27. Pontikis, R.; Dollé, V.; Guillaumel, J.; Deschaux, E.; Note, R.; Nguyen, C.H.; Legraverend, M.; Bisagni, E.; Aubertin, A.-M.; Grierson, D.S.; Monneret, C. Synthesis and Evaluation of "AZT-HEPT," "AZT-pyridinone," and "ddCHEPT" conjugates as inhibitors of HIV reverse transcriptase. J. Med. Chem. 2000, 43, 1927-1939.
28. Kohlstaedt, L.A.; Wang, J.; Friedman, J.M.; Rice, P.A.; Steitz, T.A. Related articles, protein, structure, crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256, 1783-1790.
29. Adams, D.R.; Perez, C.; Maillard, M.; Florent, J.-C.; Evers, M.; Hénin, Y.; Litvak, S.; Litvak, L.; Monneret, C.; Grierson, D.S. Preparation and anti-HIV activity of N-3-substituted thymidine nucleoside analogs. J. Med. Chem. 1997, 40, 1550-1558.
30. Bell, F.W.; Cantrell, A.S.; Högberg, M.; Jaskunas, S.R.; Johansson, N.G.; Jordan, C.L.; Kinnick, M.D.; Lind, P.; Morin, J.M. Jr.; Noréen, R.; Oberg, B.; Palkovitz, J.A.; Parrish, C.A.; Pranc, P.; Sahlberg, C.; Ternansky, R.J.; Vasileff, R.T.; Vrang, L.; West, S.J.; Zhang, H.; Zhou, X.-X. Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J. Med. Chem. 1995, 38, 4929-4936.
31. Ahgren, C.; Backro, K.; Bell, F.W.; Cantrell, S.; Clemens, M.; Colacino, J.M.; Deter, J.B.; Engelhardt, J.A.; Ogberg, M.; Jaskunas, S.R.; Jonhansson, N.G.; Jordan, C.L.; Kasher, J.S.; Kinnik, M.D.; Lind, P.; Lopez, C.; Morin, J.M. Jr.; Muesing, M.A.; Noreen, R.; Oberg, B. et al. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 1995, 39, 1329-1335.
32. Cantrell, S.A.; Engelhardt, P.; Högberg, M.; Jaskunas, S.R.; Johansson, N.G.; Jordan, C.L.; Kangasmetsä, J.; Kinnik, M.D.; Lind, P.; Morin, J.M. Jr.; Muesing, J.M. Jr.; Noréen, R.; Oberg, B.; Pranc, P.; Sahlberg, C.; Ternansky, R.J.; Vasileff, R.T.; Wrang, L.; West, S.J.; Zhang, H. Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. J. Med. Chem. 1996, 39, 4261-4274.
33. Vig, R.; Mao, C.; Venkatachalam, T.K.; Tuel-Ahlgren, L.; Sudbeck, E.A.; and Uckun, F.M. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reserve transcriptase. Bioorg. Med. Chem. 1998, 6, 1789-1797.
34. Mao, C.; Vig, R.; Venkatachalam, T.K.; Sudbeck, E.A.; Uckun, F.M. Structure-based design of N-[2-(1-piperidinylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)]-N'-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 1998, 8, 2213-2218.
35. Ciurea, A.; Fossey, C.; Benzaria, S.; Gavriliu, D.; Delbederi, Z.; Lelong, B.; Ladurée, D.; Aubertin, A.M.; and Kirn, A. Synthesis of 5-alkenylated D4T analogues via the Pd-datalyzed cross-coupling reaction. Nucleosides, Nucleotides & Nucleic Acids 2001, 20, 1655-1670.
36. Shiragami, H.; Irie, Y.; Shirae, H.; Yokozeki, K.; Yasuda, N. Synthesis of 2′,3′-dideoxyuridine via deoxygenation of 2′,3′-O-(methoxymethylene)uridine. J. Org. Chem. 1988, 53, 5170-5173.
37. Marumoto, R.; Honjo, M. One-step Halogenation at the 2′-position of uridine and related reaction of cytidine and N'-acetylcytidine. Chem. Pharm. Bull. 1974, 22, 128-134.
38. Kozak, J.; Johnson, C. Synthesis of 4′-trifluoromethyl nucleoside analogs. Nucleosides & Nucleotides 1998, 17, 2221-2239.
39. Shiragami, H.; Ineyama, T.; Uchida, Y.; Izawa, K. Synthesis of 1-(2,3-dideoxy-β-D-glycero-pent-2-enofuranosyl)thymine (d4T; stavudine) from 5-methyluridine. Nucleosides & Nucleotides 1996, 15, 47-58.
40. Moog, C.; Wick, A.; Le Ber, P.; Kirn, A.; Aubertin, A.M. Bicyclic imidazo derivatives, a new class of highly selective inhibitors for the human immunodeficiency virus type 1. Antiviral Res. 1994, 24, 275-288.
41. Chou, J.; Chou, T.C. Dose-effect analysis with microcomputers: Quantitation of ED50, LD50, synergism, anatgonism, low-dose risk, receptor binding and enzyme kinetics. In Computer Software for Apple II Series and IBM-PC and Instruction Manual; Elsevier-Biosoft: Cambridge, 1985; 19-28.
42. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
43. Lefèbvre, I.; Périgaud, C.; Pompon, A.; Aubertin, A.M.; Girardet, J.L.; Kirn, A.; Gosselin, G.; Imbach, J.L. Mononucleoside phosphotriester derivatives with S-acyl-2-thioethyl bioreversible phosphate-protecting groups: Intracellular delivery of 3′-Azido-2′,3′-dideoxythymidine 5′-monophosphate. J. Med. Chem. 1995, 38, 3941-3950.